

Special Issue

Nrf2 at the Crossroads of Molecular Mechanisms in Health and Disease

Message from the Guest Editors

The transcription factor NRF2 has been studied extensively in recent years, and is primarily associated with the regulation of the redox balance in the body. It is a specific cellular transmitter of signals, stimulated by a number of factors related to oxidative stress and inflammation. Recent studies report that the chronic activation of the NRF2 pathway may contribute to the development of reductive stress and intensify the inflammatory process, resulting in disease progression. In order to build a pharmacological therapy based on the activation of NRF2, let us try to explain the consequence of its overexpression in both health and disease. Let us find answers to the questions asking how we might stimulate/induce the NRF2 pathway so as not to lead to the harmful dysregulation of the redox system in the body. The idea behind this Special Issue is therefore to assemble papers exploring the ups and downs of the NRF2 signaling pathway, both in physiological conditions and in disease.

Guest Editors

Dr. Magdalena Paulina Kasprzak

Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Science, Rokietnicka 8, 60-806 Poznan, Poland

Prof. Dr. Dorota Formanowicz

Department of Medical Chemistry and Laboratory Medicine Poznan, University of Medical Sciences, 61-701 Poznan, Poland

Deadline for manuscript submissions

closed (31 August 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/182069

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).